Fibrosis is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Fibrosis occurs in many different diseases, and it has been estimated that dysregulated fibrosis results in 45% of all deaths. Excessive fibrous tissue can impair the normal functioning of various organs in the body, such as the lungs, liver, heart and kidneys, resulting in major health issues.
Focal Adhesion Kinase (FAK) plays an important role in fibrotic disease. Amplia’s FAK inhibitors have been shown to block fibrosis in established models of both lung fibrosis (IPF) and liver fibrosis (NASH).
Amplia's FAK Inhibitors in an animal model of lung fibrosis
Amplia's FAK Inhibitors in an animal model of liver fibrosis
Amplia is planning to initiate a Phase 2 clinical trial of narmafotinib (AMP945) in patients with Idiopathic Pulmonary Fibrosis (IPF or lung fibrosis) and is currently evaluating narmafotinib in preclinical models of various fibrotic diseases.